Fenoldopam mesylate en es it fr

Fenoldopam mesylate Brand names, Fenoldopam mesylate Analogs

Fenoldopam mesylate Brand Names Mixture

  • No information avaliable

Fenoldopam mesylate Chemical_Formula

C20H32F2O5

Fenoldopam mesylate RX_link

No information avaliable

Fenoldopam mesylate fda sheet

Fenoldopam_mesylate FDA

Fenoldopam mesylate msds (material safety sheet)

Fenoldopam mesylate Synthesis Reference

No information avaliable

Fenoldopam mesylate Molecular Weight

390.462 g/mol

Fenoldopam mesylate Melting Point

No information avaliable

Fenoldopam mesylate H2O Solubility

Practically insoluble

Fenoldopam mesylate State

Solid

Fenoldopam mesylate LogP

4.453

Fenoldopam mesylate Dosage Forms

Capsule (24 µg)

Fenoldopam mesylate Indication

For the treatment of chronic idiopathic constipation in the adult population.

Fenoldopam mesylate Pharmacology

Chronic idiopathic constipation is generally defined by infrequent or difficult passage of stool. The signs and symptoms associated with chronic idiopathic constipation (i.e., abdominal pain or discomfort, bloating, straining, and hard or lumpy stools) may be the result of abnormal colonic motility that can delay the transit of intestinal contents and impede the evacuation of rectal contents. One approach to the treatment of chronic idiopathic constipation is the secretion of fluid into the abdominal lumen through the activation of chloride channels in the apical membrane of the gastrointestinal epithelium. Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum.

Fenoldopam mesylate Absorption

Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).

Fenoldopam mesylate side effects and Toxicity

In a definitive Phase 1 cardiac repolarization study, 51 patients were administered a single oral dose of 144 mcg of lubiprostone, which is 6 times the normal single administration dose. Thirty-nine (39) of the 51 patients experienced an adverse event. The adverse events reported in >1% of this group included the following: nausea (45.1%), vomiting (27.5%), diarrhea (25.5%), dizziness (17.6%), loose or watery stools (13.7%), headache (11.8%), retching (7.8%), abdominal pain (5.9%), flushing or hot flush (5.9%), dyspnea (3.9%), pallor (3.9%), stomach discomfort (3.9%), syncope (3.9%), upper abdominal pain (2.0%), anorexia (2.0%), asthenia (2.0%), chest discomfort (2.0%), dry mouth (2.0%), hyperhidrosis (2.0%), skin irritation (2.0%) and vasovagal episode (2.0%).

Fenoldopam mesylate Patient Information

No information avaliable

Fenoldopam mesylate Organisms Affected

Humans and other mammals